These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 12890913)

  • 21. Expression of platelet surface receptors and early changes in platelet function in patients with STEMI treated with abciximab and clopidogrel versus clopidogrel alone.
    Konopka A; Spychalska J; Sitkiewicz D; Zdebska E; Pilichowska I; Piotrowski W; Stepińska J
    Am J Cardiovasc Drugs; 2007; 7(6):433-9. PubMed ID: 18076210
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Disaggregation Following Agonist-Induced Platelet Activation in Patients on Dual Antiplatelet Therapy.
    Wadowski PP; Eichelberger B; Kopp CW; Pultar J; Seidinger D; Koppensteiner R; Lang IM; Panzer S; Gremmel T
    J Cardiovasc Transl Res; 2017 Aug; 10(4):359-367. PubMed ID: 28425039
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Increased platelet aggregability in response to shear stress in acute myocardial infarction and its inhibition by combined therapy with aspirin and cilostazol after coronary intervention.
    Tanigawa T; Nishikawa M; Kitai T; Ueda Y; Okinaka T; Makino K; Ito M; Isaka N; Ikeda Y; Shiku H; Nakano T
    Am J Cardiol; 2000 May; 85(9):1054-9. PubMed ID: 10781751
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antiplatelet effects of clopidogrel compared with aspirin after myocardial infarction: enhanced inhibitory effects of combination therapy.
    Moshfegh K; Redondo M; Julmy F; Wuillemin WA; Gebauer MU; Haeberli A; Meyer BJ
    J Am Coll Cardiol; 2000 Sep; 36(3):699-705. PubMed ID: 10987587
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Optimizing platelet P2Y12 inhibition for patients undergoing PCI.
    Steinhubl S; Roe MT
    Cardiovasc Drug Rev; 2007; 25(2):188-203. PubMed ID: 17614940
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition by combined therapy with ticlopidine and aspirin of enhanced platelet aggregation during physical exercise in patients with coronary artery disease.
    Kitai T; Nishikawa M; Tanigawa T; Okinaka T; Wada H; Shiku H; Ikeda Y; Ito M; Isaka N; Nakano T
    Am Heart J; 2001 Aug; 142(2):E1. PubMed ID: 11479480
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Compliance with antiplatelet therapy in patients with ischemic cerebrovascular disease. Assessment by platelet aggregation testing.
    Komiya T; Kudo M; Urabe T; Mizuno Y
    Stroke; 1994 Dec; 25(12):2337-42. PubMed ID: 7974570
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Double-blind, randomized, prospective comparison of loading doses of 600 mg clopidogrel versus 60 mg prasugrel in patients with acute ST-segment elevation myocardial infarction scheduled for primary percutaneous intervention: the ETAMI trial (early thienopyridine treatment to improve primary PCI in patients with acute myocardial infarction).
    Zeymer U; Mochmann HC; Mark B; Arntz HR; Thiele H; Diller F; Montalescot G; Zahn R
    JACC Cardiovasc Interv; 2015 Jan; 8(1 Pt B):147-154. PubMed ID: 25616919
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In Vitro Effects of Pantoprazole on Platelet Aggregation in Blood Samples From Clopidogrel and Aspirin-treated Patients.
    Karlsson E; Holm M; van der Linden JA
    J Cardiovasc Pharmacol; 2016 Sep; 68(3):191-5. PubMed ID: 27110745
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development of large platelet aggregates from small aggregates as determined by laser-light scattering: effects of aggregant concentration and antiplatelet medication.
    Tohgi H; Takahashi H; Watanabe K; Kuki H; Shirasawa Y
    Thromb Haemost; 1996 May; 75(5):838-43. PubMed ID: 8725733
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The lack of augmentation by aspirin of inhibition of platelet reactivity by ticlopidine.
    Farrell TP; Hayes KB; Sobel BE; Schneider DJ
    Am J Cardiol; 1999 Mar; 83(5):770-4. PubMed ID: 10080435
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of antiplatelet drugs in the prevention of cardiovascular events.
    Tendera M; Wojakowski W
    Thromb Res; 2003 Jun; 110(5-6):355-9. PubMed ID: 14592562
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Platelet inhibition by abciximab bolus-only administration and oral ADP receptor antagonist loading in acute coronary syndrome patients: the blocking and bridging strategy.
    Christ G; Hafner T; Siller-Matula JM; Francesconi M; Grohs K; Wilhelm E; Podczeck-Schweighofer A
    Thromb Res; 2013 Jul; 132(1):e36-41. PubMed ID: 23791395
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Platelet responsiveness to clopidogrel in patients with coronary syndrome. Comparison of platelet aggregation induced by ADP and flow cytometric analysis of intraplatelet VASP phosphorylation].
    Morel O; Viellard C; Faure A; Jesel L; Ohlmann P; Desprez D; Chauvin M; Roul G; Grunebaum L; Bareiss P
    Ann Cardiol Angeiol (Paris); 2007 Jan; 56(1):21-9. PubMed ID: 17343035
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reversal of the anti-platelet effects of aspirin and clopidogrel.
    Li C; Hirsh J; Xie C; Johnston MA; Eikelboom JW
    J Thromb Haemost; 2012 Apr; 10(4):521-8. PubMed ID: 22268852
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterization of platelet aggregation responses in microminipigs: Comparison with miniature pigs and the influence of dual antiplatelet administration of aspirin plus prasugrel.
    Ohno K; Tomizawa A; Jakubowski JA; Mizuno M; Sugidachi A
    Thromb Res; 2015 May; 135(5):933-8. PubMed ID: 25776467
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of clinical parameters and of CYP2C19 G681 and CYP4F2 G1347A polymorphisms on platelet reactivity during dual antiplatelet therapy.
    Tatarunas V; Jankauskiene L; Kupstyte N; Skipskis V; Gustiene O; Grybauskas P; Lesauskaite V
    Blood Coagul Fibrinolysis; 2014 Jun; 25(4):369-74. PubMed ID: 24418943
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomized pilot trial for aggressive therapeutic approaches in aspirin-resistant patients undergoing percutaneous coronary intervention.
    El-Atat F; Sarkar K; Kodali V; Karajgikar R; Jakkulla M; Mares A; Sharma S; Kini A
    J Invasive Cardiol; 2011 Jan; 23(1):9-13. PubMed ID: 21183763
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pantoprazole may enhance antiplatelet effect of enteric-coated aspirin in patients with acute coronary syndrome.
    Kasprzak M; Koziński M; Bielis L; Boinska J; Plazuk W; Marciniak A; Budzyński J; Siller-Matula J; Rość D; Kubica J
    Cardiol J; 2009; 16(6):535-44. PubMed ID: 19950090
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Residual cyclooxygenase-1 activity and epinephrine reduce the antiplatelet effect of aspirin in patients with acute myocardial infarction.
    Moscardó A; Santos MT; Fuset MP; Ruano M; Vallés J
    Thromb Haemost; 2011 Apr; 105(4):663-9. PubMed ID: 21301784
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.